Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor …,

PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for …, PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for …, Read More

Scroll to Top